For following the competition: what moved in each program, several studies read as one move.
- nor-ursodeoxycholic acid
- elifibranor
- LB-P8 low-dose
- + 2 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Cholangitis, Sclerosing to watchlistEvery Monday by email · turn it off any timePro · free during the beta